eFT 508

Drug Profile

eFT 508

Alternative Names: eFT-508

Latest Information Update: 07 Apr 2017

Price : $50

At a glance

  • Originator Effector Therapeutics
  • Class Antineoplastics
  • Mechanism of Action MKNK1 protein inhibitors; MKNK2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Diffuse large B cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Cancer; Lymphoma
  • Preclinical Diffuse large B cell lymphoma

Most Recent Events

  • 03 Apr 2017 Preclinical pharmacodynamics data in Cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2017)
  • 09 Mar 2017 eFT 508 receives Orphan Drug status for Diffuse large B cell lymphoma in USA
  • 01 Oct 2016 Phase-I/II clinical trials in Lymphoma in USA (PO) (NCT02937675)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top